PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2147148
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2147148
The global mammography market was valued at USD 13.86 billion in 2025 and is projected to reach USD 14.31 billion in 2026 and USD 19.37 billion by 2034, registering a CAGR of 3.9% during the forecast period. North America dominated the market with a 73.09% share in 2025, supported by advanced healthcare infrastructure, favorable reimbursement policies, established breast cancer screening programs, and high adoption of advanced breast imaging technologies. Mammography remains a critical imaging technique for breast cancer screening and diagnosis, with increasing demand supported by rising disease incidence and growing awareness of early detection.
Market Definition and Scope
Mammography comprises imaging services and technologies used to detect, diagnose, and monitor breast abnormalities, particularly breast cancer. The market includes screening mammography services, diagnostic mammography services, and mammography-guided interventional services. Imaging modalities include 2D digital mammography, 3D digital breast tomosynthesis (DBT), contrast-enhanced mammography, and other technologies. Increasing integration of artificial intelligence, improved image visualization, and risk-based screening approaches are expanding the scope of mammography services across hospitals, specialty clinics, and diagnostic centers.
Market Dynamics
Drivers
The expansion of organized breast cancer screening programs is a major driver of market growth. Governments, healthcare organizations, and cancer societies are increasing screening awareness and encouraging routine examinations to support early cancer detection. Growing healthcare expenditure, improved diagnostic infrastructure, and increasing adoption of advanced breast imaging are further supporting market expansion. In April 2026, the NCCN updated breast cancer screening guidelines to include AI-based mammogram risk assessment beginning at age 35, highlighting the increasing role of technology-supported personalized screening.
Trends
A major trend is the growing adoption of AI-enabled 3D digital breast tomosynthesis. In 2025, the 3D DBT services segment accounted for 50.6% of the global market. DBT provides multiple breast images from different angles, improving tissue visualization and reducing tissue overlap. AI-supported systems further assist radiologists in identifying suspicious lesions, prioritizing cases, and improving workflow efficiency. In April 2026, GE HealthCare expanded its collaboration with DeepHealth to globally commercialize AI-powered mammography solutions integrating Breast Suite with Pristina Via.
Restraints
The high cost of advanced mammography systems remains a key market restraint. DBT systems, AI-enabled imaging software, and contrast-enhanced mammography platforms require significant investment in equipment, infrastructure, maintenance, and trained professionals. Smaller hospitals and rural diagnostic centers may face difficulties adopting these technologies, particularly in markets where healthcare funding and reimbursement coverage remain limited.
Impact of COVID-19
The COVID-19 pandemic temporarily disrupted mammography services because of postponed screening appointments, healthcare facility restrictions, and reduced patient visits. However, the market gradually recovered as healthcare systems resumed preventive screening programs. Increased emphasis on early diagnosis and the adoption of digital healthcare technologies subsequently supported the recovery of mammography screening volumes.
By Service
The market is segmented into screening mammography services, diagnostic mammography services, and mammography-guided interventional services. Screening mammography services held a major position in 2025, supported by preventive healthcare initiatives, increasing breast cancer awareness, and organized screening programs. Mammography-guided interventional services are projected to grow at a 5.9% CAGR during the forecast period, supported by increasing demand for image-guided breast procedures.
By Imaging Modality
The market includes 2D digital mammography services, 3D digital breast tomosynthesis services, contrast-enhanced mammography services, and others. The 3D DBT segment held a 50.6% share in 2025, supported by improved tissue visualization and diagnostic performance. Contrast-enhanced mammography services are expected to expand at a 5.3% CAGR, supported by increasing utilization in complex breast imaging examinations.
By End User
The end-user segment comprises hospitals, specialty clinics, diagnostic centers, and others. Hospitals held the leading position in 2025 due to advanced imaging infrastructure and integrated breast cancer care. The hospitals segment is expected to account for 43.9% in 2026. Specialty clinics are projected to grow at a 4.5% CAGR during the forecast period.
North America remained the largest regional market, reaching USD 10.13 billion in 2025. The region benefits from advanced healthcare infrastructure, favorable reimbursement, established screening programs, and high adoption of AI and DBT technologies. The U.S. market is expected to reach approximately USD 10.11 billion in 2026, representing about 70.6% of global market value.
Europe is expected to reach USD 2.13 billion in 2026, supported by population-based screening programs and advanced diagnostic infrastructure. The U.K. market is estimated at approximately USD 0.24 billion, while Germany is projected at approximately USD 0.40 billion in 2026.
Asia Pacific is projected to reach USD 1.18 billion in 2026, supported by rising breast cancer incidence, increasing healthcare expenditure, and improving diagnostic infrastructure. China is expected to reach approximately USD 0.51 billion, Japan approximately USD 0.33 billion, and India approximately USD 0.08 billion in 2026.
Latin America is projected to reach approximately USD 0.34 billion in 2026, while the GCC market is expected to reach USD 0.08 billion. South Africa is projected to reach approximately USD 0.03 billion in 2026.
Competitive Landscape
The global mammography market has a semi-consolidated structure, with leading companies focusing on collaborations, technology development, imaging infrastructure expansion, and AI-enabled services. Major companies include RadNet, Inc., InHealth Group, SimonMed Imaging, Akumin Inc., Fortis Healthcare Ltd., Affidea Group, Unilabs, Evidia Group, and I-MED Radiology Network.
In June 2026, FUJIFILM India announced the first installation of its AI-powered AMULET SOPHINITY digital mammography system at NM Medical in India. The system combines low-dose imaging, AI-assisted workflows, and enhanced visualization.
Key Industry Developments
Report Coverage
The global mammography market report covers market size and forecast data for 2025, 2026, and 2034, along with market dynamics, trends, segmentation by service, imaging modality, and end user, and regional analysis. The report also examines technological advancements, AI integration, screening programs, regulatory developments, partnerships, competitive strategies, and key industry developments. Major companies profiled include RadNet, Inc., InHealth Group, SimonMed Imaging, Akumin Inc., Fortis Healthcare Ltd., Affidea Group, Unilabs, Evidia Group, and I-MED Radiology Network.
Conclusion
The global mammography market, valued at USD 13.86 billion in 2025, is projected to increase to USD 14.31 billion in 2026 and reach USD 19.37 billion by 2034 at a 3.9% CAGR. Expanding breast cancer screening programs, increasing adoption of 3D DBT, AI-enabled mammography, personalized screening strategies, and improving diagnostic infrastructure will remain important growth factors. North America's 73.09% market share in 2025 demonstrates its strong market leadership, while Asia Pacific is expected to offer significant future opportunities as healthcare infrastructure and breast cancer awareness continue to improve.
Segmentation By Service, Imaging Modality, End-User, and Region
By Service
By Imaging Modality
By End-User
By Region